HealthTree Foundation

#myeloma #leukemia #lymphoma #MPNs #aml #cll #mds #dlbcl #myelofibrosis #follicularlymphoma #healthtree

[HealthTree Foundation @HealthTree]

🚨 The FDA has approved Sarclisa Escena® (isatuximab-irfc), a new subcutaneous formulation of isatuximab for multiple myeloma, offering another administration option beyond IV infusion. https://t.co/9TxOd3BJ7A

@Sanofi

#MultipleMyeloma #FDAApproval #BloodCancer

[@MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher]

ICYMI: Catch up on the latest multiple #myeloma research from #EHA2026! Explore @HealthTree’s EHA playlist featuring expert interviews, study highlights, and key takeaways from the meeting.

https://t.co/WLALlyRwoS

[HealthTree Foundation @HealthTree]

Congratulations to everyone recognized in @OncoDaily's Top 100 Influential Cancer Survivors of 2026! 👏We're proud to see HealthTree community members among this inspiring group. 💙
https://t.co/mKgc826VxL

@MyelomaTeacher

[@MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher]

A New Frontier in #Myeloma: mRNA-2808 Targets BCMA, GPRC5D & FcRH5 with One Therapy | ASCO 2026 #mmsm @HealthTree
https://t.co/1udS72GZ1T

[EasyM: Blood-based MRD for MM @easym_test]

Check out the latest @HealthTree interview with our Senior Scientist where they discuss our newest research on EasyM, our blood-based MRD test for multiple myeloma 🩸

Watch the interview to learn more 🎥 : https://t.co/HOML8FaoH1

EasyM is currently available for patients in the US and Canada.

#MultipleMyeloma #MRD #MM #Hematology #MMSM #EHA2026

[@MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher]

MajesTEC-9 Results : Teclistamab Outperforms PVd & Kd in Relapsed #Myeloma: | EHA 2026 #mmsm @RobertoMina_MD @HealthTree
https://t.co/wRMHJe6J74

[Vumedi Oncology @VuMediHemOnc]

🩺How should the MajesTEC-9 and MajesTEC-3 data influence treatment decisions in multiple myeloma?

In the latest installment of the Miami Myeloma Cross-Country series, Dr. Dickran Kazandjian (@DrKazandjian) leads a discussion with Drs. Benjamin Derman (@bdermanmd), Ola Landgren (@DrOlaLandgren), and Kenneth Shain on how the ASCO 2026 findings from MajesTEC-9 and MajesTEC-3 may reshape treatment decisions in relapsed multiple myeloma.

The panel explores how to sequence CAR T-cell therapy and bispecific antibodies, when a non-BCMA strategy may be preferred, and what these landmark studies mean for bringing BCMA-directed therapies into earlier lines of treatment.

🎥 Watch on Vumedi: https://t.co/be62I5G69z

🔗 Visit the Miami Myeloma Cross-Country Vumedi Channel to keep up with hot topics in myeloma: https://t.co/7GZmxNT4W6

Featuring experts from @SylvesterCancer / @UMiamiHealth, @MoffittNews, and @UCCancerCenter / @UChicagoMed

With thanks to organizations advancing myeloma research and care, including @theMMRF, @IMFmyeloma, @HealthTree, @ASH_hematology, @AmericanCancer, @Myeloma_Society and @ConquerCancerFd

#MMSM #ASCO26

[HealthTree Foundation @HealthTree]

Looking to optimize sequential care in relapsed/refractory multiple myeloma with CELMoDs? Watch Drs. Sagar Lonial (@SagarLonialMD), Nizar Jacques Bahlis (@NBahlis) and Krina Patel (@DrKrinaPatel) with our partners @PeerView on evidence, sequencing and safety: https://t.co/jEEkVUUbFG #MedEd #ASCO26

[HealthTree Foundation @HealthTree]

🚨 FDA approves Tregzi, a new immunotherapy designed to improve stem cell transplant outcomes for adults with certain blood cancers by reducing the risk of chronic graft-versus-host disease (cGVHD).
A promising step forward in blood cancer treatment. 💚 https://t.co/e1P8wFG50R
#BloodCancer #FDAApproval #StemCellTransplant #HealthTree

[HealthTree Foundation @HealthTree]

https://t.co/Fp9F7RfCdW

[HealthTree Foundation @HealthTree]

Diagnosed with #MultipleMyeloma at 42. Ran nearly 1,200 miles after a bone marrow transplant.
Kenny Capps shares his journey of resilience, recovery, and life beyond cancer in this powerful conversation for #MensHealthMonth.

[@MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher]

MajesTEC-4 / EMN30 Trial: Is Teclistamab the Future of #Myeloma Maintenance After Transplant? | EHA26 #mmsm
https://t.co/COMzgE66jt

[@KinatSofrim @kinatsofrim]

@harrisoncn1 @sk_tantravahi @DrNeilLove @FudanUniversity @KartosThera @pec_panco_Alex @rosslevinemd @bradloncar @BiotechTV @megkesh @bose_prithviraj @ecancer @UniLeipzig @peter_mpn @RaajitRampal @HealthTree $KPTI Thank you @harrisoncn1 h/t @HealthTree "Lookout for 48 week data [ASH 2026]"

/452

[HealthTree Foundation @HealthTree]

Life after a blood cancer diagnosis comes with new challenges, but you don't have to face them alone. 💙
Watch our latest video to explore resources, tools, and support for every stage of survivorship. #CancerSurvivor

[@MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher]

Relapsed/Refractory Multiple #Myeloma Highlights from EHA | EHA 2026 @rahulbanerjeeMD #mmsm @healthtree
https://t.co/COfxVE0lhp

[@MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher]

TRIlogy-4: Ramantamig’s Triple Target Attack on #Myeloma—BCMA, GPRC5D, an... https://t.co/mg39fWYg1Y @HealthTree #mmsm

[Dickran Kazandjian, MD @DrKazandjian]

With MRD-Driven Accelerated Approvals, Efficacious Multiple Myeloma Drugs Are Reaching Patients More Quickly and Providing Functional Cures Sooner https://t.co/GyGbtETMOR @DrOlaLandgren @SylvesterCancer @ASCOPost @HealthTree

[@MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher]

LINKER-MM1: Linvoseltamab Shows Promise Across High-Risk #Myeloma | EHA 2026
https://t.co/IPN5ZEIdO5 @DottorClaudio @HealthTree #mmsm

[@MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher]

Venetoclax + Ibrutinib Overcomes Drug Resistance in CLL: Long-Term Results #CLL
https://t.co/yrzZiDFc6J @healthtree

[HealthTree Foundation @HealthTree]

As treatment options expand in #CLL, how can clinicians optimize sequencing decisions to maximize long-term benefit? Join @PeerView live virtually on 6/25 at 12:00 PM EDT for expert insights on prognostic testing, targeted therapies, and patient-centered treatment planning. Register: https://t.co/QozT9zcmZE  #EHA2026 #MedEd